Drug Trial Radar · NCT06713590
A Study to Evaluate a Single-Dose Subcutaneous Axatilimab Compared With Intravenous Axatilimab in Healthy Participants
Last checked: Nov 20, 2026Latest source record: Jun 25, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
Jan 14, 2025
Primary completion
Jun 6, 2025
Study completion Jun 10, 2025
Sponsor
- Lead sponsor
- Incyte CorporationIncyte (INCY)
- Sponsor type
- Industry
- First posted
- Dec 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will be conducted to evaluate a Single-Dose Subcutaneous (SC) Axatilimab Compared With Intravenous Axatilimab in Healthy Participants.
Conditions
- Healthy Participants
Interventions
AxatilimabDrug
Axatilimab will be administered at protocol defined dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Pharmacokinetics Parameter: Cmax of axatilimabTime frame: Pre dose and Post dose on Day 1, Post dose Days 2, 3, 4, 6, 8, 15, 22, 28 and 60
- Pharmacokinetics Parameter: AUC(0-t) of axatilimabTime frame: Pre dose and Post dose on Day 1, Post dose Days 2, 3, 4, 6, 8, 15, 22, 28 and 60
- Pharmacokinetics Parameter: AUC 0-∞ of axatilimabTime frame: Pre dose and Post dose on Day 1, Post dose Days 2, 3, 4, 6, 8, 15, 22, 28 and 60
- Number of participants with Treatment Emergent Advers Events (TEAE's)Time frame: Up to 3 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Celerion, Inc
Tempe, Arizona
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.